Rheumatoid Arthritis and Risk of Parkinson Disease in Korea.
暂无分享,去创建一个
Jihun Kang | K. Han | W. Jang | Jin-Hyung Jung | M. Cho | Hyungjin Kim | Y. Eun | D. Shin | Yunkyung Kim | Gun-Tae Kim
[1] B. Cho,et al. National General Health Screening Program in Korea: history, current status, and future direction: A scoping review , 2022, Precision and Future Medicine.
[2] D. Shin,et al. Sex differences in the association between nonalcoholic fatty liver disease and Parkinson's disease. , 2021, Parkinsonism & related disorders.
[3] M. Mielke,et al. POS0309 SEROPOSITIVITY INCREASES RISK OF INCIDENT DEMENTIA IN INDIVIDUALS WITH RHEUMATOID ARTHRITIS: A POPULATION-BASED COHORT STUDY , 2021, Annals of the Rheumatic Diseases.
[4] L. Brundin,et al. Decreased Risk of Parkinson’s Disease After Rheumatoid Arthritis Diagnosis: A Nested Case-Control Study with Matched Cases and Controls , 2021, Journal of Parkinson's disease.
[5] D. Shin,et al. Female reproductive factors and the risk of Parkinson’s disease: a nationwide cohort study , 2020, European Journal of Epidemiology.
[6] S. Rhee,et al. Association Between Glycemic Status and the Risk of Parkinson Disease: A Nationwide Population-Based Study , 2020, Diabetes Care.
[7] J. Jankovic,et al. Parkinson disease and the immune system — associations, mechanisms and therapeutics , 2020, Nature Reviews Neurology.
[8] S. Rhee,et al. Body Mass Index, Diabetes, and the Risk of Parkinson's Disease , 2019, Movement disorders : official journal of the Movement Disorder Society.
[9] Kyungdo Han,et al. Trends in the incidence and prevalence of Parkinson’s disease in Korea: a nationwide, population-based study , 2019, BMC Geriatrics.
[10] K. Choi,et al. Chronic renal dysfunction, proteinuria, and risk of Parkinson's disease in the elderly , 2019, Movement disorders : official journal of the Movement Disorder Society.
[11] D. Shin,et al. Association of statin use with Parkinson's disease: Dose–response relationship , 2019, Movement disorders : official journal of the Movement Disorder Society.
[12] M. Dubinsky,et al. Anti–Tumor Necrosis Factor Therapy and Incidence of Parkinson Disease Among Patients With Inflammatory Bowel Disease , 2018, JAMA neurology.
[13] W. Poewe,et al. Validation of the MDS clinical diagnostic criteria for Parkinson's disease , 2018, Movement disorders : official journal of the Movement Disorder Society.
[14] Yu-Sheng Chang,et al. Autoimmune rheumatic diseases and the risk of Parkinson disease: a nationwide population-based cohort study in Taiwan , 2018, Annals of medicine.
[15] Nicholas W Wood,et al. Genome-wide Pleiotropy Between Parkinson Disease and Autoimmune Diseases , 2017, JAMA neurology.
[16] N. Chen,et al. Pathological α-synuclein exacerbates the progression of Parkinson's disease through microglial activation. , 2017, Toxicology letters.
[17] Hee-Jin Kang,et al. Data Resource Profile: The National Health Information Database of the National Health Insurance Service in South Korea , 2016, International journal of epidemiology.
[18] Y. Chou,et al. Reduced Risk of Parkinson Disease in Patients With Rheumatoid Arthritis: A Nationwide Population-Based Study. , 2016, Mayo Clinic proceedings.
[19] V. Manganelli,et al. Autophagy generates citrullinated peptides in human synoviocytes: a possible trigger for anti-citrullinated peptide antibodies. , 2016, Rheumatology.
[20] Lawrence H. Kushi,et al. Recent Trends in Cardiovascular Mortality in the United States and Public Health Goals. , 2016, JAMA cardiology.
[21] E. Keystone,et al. Prognosis of Seronegative Patients in a Large Prospective Cohort of Patients with Early Inflammatory Arthritis , 2014, The Journal of Rheumatology.
[22] S. Bae,et al. Development of an algorithm for identifying rheumatoid arthritis in the Korean National Health Insurance claims database , 2013, Rheumatology International.
[23] R. Nixon,et al. The role of autophagy in neurodegenerative disease , 2013, Nature Medicine.
[24] F. Pitossi,et al. Interleukin-1β and tumor necrosis factor-α: reliable targets for protective therapies in Parkinson’s Disease? , 2013, Frontiers in Cellular Neuroscience.
[25] J. Sundquist,et al. Subsequent Risks of Parkinson Disease in Patients with Autoimmune and Related Disorders: A Nationwide Epidemiological Study from Sweden , 2011, Neurodegenerative Diseases.
[26] E. Unanue,et al. Autophagy in antigen-presenting cells results in presentation of citrullinated peptides to CD4 T cells , 2011, The Journal of experimental medicine.
[27] Georg Schett,et al. The pathogenesis of rheumatoid arthritis. , 2011, The New England journal of medicine.
[28] I. Ferrer,et al. Chaperone-mediated autophagy markers in Parkinson disease brains. , 2010, Archives of neurology.
[29] M. Vila,et al. Pathogenic Lysosomal Depletion in Parkinson's Disease , 2010, The Journal of Neuroscience.
[30] A. Barton,et al. Benefit of early treatment in inflammatory polyarthritis patients with anti–cyclic citrullinated peptide antibodies versus those without antibodies , 2010, Arthritis care & research.
[31] M. Farrer,et al. LRRK2 and Parkinson disease. , 2010, Archives of neurology.
[32] S. Rexhepi,et al. Extra-articular manifestations of seronegative and seropositive rheumatoid arthritis. , 2010, Bosnian journal of basic medical sciences.
[33] J. Olsen,et al. Autoimmune disease and risk for Parkinson disease , 2009, Neurology.
[34] A. Ascherio,et al. Family history of melanoma and Parkinson disease risk , 2009, Neurology.
[35] F. Gage,et al. A Nurr1/CoREST Pathway in Microglia and Astrocytes Protects Dopaminergic Neurons from Inflammation-Induced Death , 2009, Cell.
[36] D. Sugiyama,et al. Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies , 2009, Annals of the rheumatic diseases.
[37] M. Tansey,et al. Neuroinflammatory mechanisms in Parkinson's disease: Potential environmental triggers, pathways, and targets for early therapeutic intervention , 2007, Experimental Neurology.
[38] Honglei Chen,et al. Peripheral inflammatory biomarkers and risk of Parkinson's disease. , 2007, American journal of epidemiology.
[39] C. Ferrari,et al. Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1β in the substantia nigra , 2006, Neurobiology of Disease.
[40] B. Botterman,et al. Blocking Soluble Tumor Necrosis Factor Signaling with Dominant-Negative Tumor Necrosis Factor Inhibitor Attenuates Loss of Dopaminergic Neurons in Models of Parkinson's Disease , 2006, The Journal of Neuroscience.
[41] Miguel A Hernán,et al. A meta‐analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease , 2002, Annals of neurology.
[42] R. Dobbs,et al. Association of circulating TNF‐α and IL‐6 with ageing and parkinsonism , 1999 .
[43] J. Hughes,et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.
[44] E. Guallar,et al. Association of cardiovascular health screening with mortality, clinical outcomes, and health care cost: a nationwide cohort study. , 2015, Preventive medicine.
[45] R. Feldman,et al. Environmental Toxins and Parkinson's Disease , 2005 .
[46] R. Maini,et al. The Role of Cytokines in Rheumatoid Arthritis , 1996, Journal of the Royal College of Physicians of London.